Production (Stage)
Capricor Therapeutics, Inc.
CAPR
$12.13
-$0.25-2.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -149.04% | -833.81% | -96.49% | -49.32% | -26.08% |
| Total Depreciation and Amortization | 22.36% | 22.14% | 30.63% | 40.13% | 44.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 80.42% | 29.17% | 18.52% | 32.90% | 48.76% |
| Change in Net Operating Assets | 136.48% | 19.58% | 66.21% | 3.31% | -48.34% |
| Cash from Operations | -407.21% | -27.62% | -32.38% | -30.48% | -130.13% |
| Capital Expenditure | -71.65% | -0.75% | 90.66% | 65.34% | -46.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 383.23% | -2,289.19% | -75.29% | 120.71% | -220.37% |
| Cash from Investing | 351.43% | -2,004.52% | -74.04% | 127.43% | -195.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.80% | 250.01% | 30,350.88% | -5.53% | 58,623.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.80% | 250.01% | 30,350.88% | -5.53% | 58,623.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 306.45% | -1,099.80% | 6,867.04% | 682.21% | -946.07% |